Following are the Top 5 companies based on their one-day percentage change within the 'TOP US - Healthcare Companies' theme.
Pfizer Inc. (PFE)
PFE is trading UP for the last 1 days, and it at trading at $28.52 with volume of 29,962,465 and a one day change of $0.56 (1.98%). Pfizer Inc. has a 52-week low of 22.03 and a 52-week high of $28.58. The business's 50-day moving average price is $25.38 and its 200 day moving average price is $25.34. The firm has a market cap of $159 million, a P/E ratio of 36.95, and a beta of 0.43.
Top news headlines for PFE
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning, picked Take-Two Interactive Software, Inc. (NASDAQ:TTWO).
ABBV is trading UP for the last 1 days, and it at trading at $256.69 with volume of 1,854,290 and a one day change of $1.21 (0.47%). AbbVie Inc. has a 52-week low of 189.40 and a 52-week high of $267.47. The business's 50-day moving average price is $251.18 and its 200 day moving average price is $224.98. The firm has a market cap of $451 million, a P/E ratio of 71.98, and a beta of 0.35.
Top news headlines for ABBV
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
Abacus FCF Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 58,634 shares of the company's stock, valued at approximately $14,755,000. AbbVie comprises about 2.7% of Abacus FCF
Csenge Advisory Group acquired a new position in AbbVie Inc. (NYSE: ABBV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 25,158 shares of the company's stock, valued at approximately $6,331,000. Other institutional investors and hedge funds have also bought and sold
This article was generated by KlickAnalytics data insight content engine.
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
KlickAnalytics AI
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same
analytics engine that powers every screen on this platform — so what comes back is a
number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
NVDA has averaged a 9.2% absolute move on the day after earnings
and closed higher 67% of the time. Two in three reactions land between
−4.2% and +16.3% — the distribution is skewed right,
not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with
“Screen the S&P 500 for oversold quality names.”
“Compare AAPL and MSFT over the last 5 years.”
“What moved the market today, and why?”
“Backtest a 50/200 crossover on TSLA.”
Create a free account to start askingNo credit card required. Confirm your email and the platform is open.